CRYOSITE LIMITED — Investor Presentation 2025

Aug 20, 2025

==> picture [456 x 186] intentionally omitted <==

Corporate Presentation August 2025

Cryosite Limited ASX Code: CTE www.cryosite.com

1

Disclaimer

==> picture [187 x 64] intentionally omitted <==

The following disclaimer applies to this non-confidential presentation prepared by Cryosite Limited ACN 090 919 476 (Cryosite) which is dated 21 August 2025 (Presentation). By accepting or receiving this Presentation, you acknowledge and agree to the terms set out below.

Summary information

This Presentation contains summary information about Cryosite and its activities which is current only as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act). It should be read in conjunction with Cryosite's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au. The information in this Presentation has been obtained from or based on sources believed by Cryosite to be reliable. Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Cryosite nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Reliance should not be placed on information or opinions contained in this Presentation and, subject only to any legal obligation to do so, Cryosite does not have any obligation to correct or update the content of this Presentation.

Not an offer

This Presentation is not a prospectus or other disclosure document under the Corporations Act or any other law, and will not be lodged with the Australian Securities and Investments Commission (or any other foreign regulator). This Presentation is for information purposes only. This Presentation is not, and does not constitute, an invitation or offer of securities for application, subscription, purchase or sale in any jurisdiction.

Not for release or distribution in the United States of America

This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States.

Not financial product advice

The information contained in this Presentation is not investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares in Cryosite. Any references to, or explanations of, legislation, regulatory issues or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. You are solely responsible for forming your own opinions and conclusions on such matters and the market and for making your own independent assessment of the information in this Presentation. This Presentation has been prepared without taking into account your investment objectives, financial situation or particular needs. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Any decision to buy or sell securities or other products should be made only after seeking appropriate financial advice.

Financial information

All financial information in this Presentation is in Australian dollars unless otherwise stated. The Presentation includes certain pro forma financial information. Any pro forma historical financial information provided in this Presentation is for illustrative purposes only and is not recognised as being indicative of Cryosite's views on its, nor anyone else's future financial position or performance. Any pro forma historical financial information has been prepared by Cryosite in accordance with the measurement and recognition principles, but not the disclosure requirements, prescribed by the Australian Accounting Standards (AAS). In addition, the pro forma financial information in this Presentation does not purport to be in compliance with Article 11 of Regulation S-X of the rules and regulations of the U.S. Securities and Exchange Commission. You should be aware that certain financial measures included in this Presentation are 'non-IFRS information' under ASIC Regulatory Guide 230: 'Disclosing non-IFRS financial information' published by ASIC and also 'non-GAAP financial measures' within the meaning of Regulation G under the U.S. Securities Act and are not recognised under AAS and the International Financial Reporting Standards (IFRS). Such non-IFRS financial information/non-GAAP financial measures do not have a standardised meaning prescribed by AAS or IFRS. Therefore, the non-IFRS financial information may not be comparable to similarly titled measures presented by other entities, and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. While Cryosite believes these non-IFRS financial measures provide useful information in measuring the financial performance and condition of its business, you are cautioned not to place\ undue reliance on any non-IFRS financial information/non-GAAP financial measures included in this Presentation. Certain figures, amounts, percentages, estimates, calculations of value and fractions provided in this Presentation are subject to the effect of rounding. As such, the actual calculation of these figures may differ from the figures set out in this Presentation.

Past performance

The past performance and position of Cryosite reflected in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Cryosite's views on its future financial performance or condition. Past performance of Cryosite cannot be relied upon as an indicator of (and provides no guidance as to) the future performance of Cryosite, including future share price performance. Nothing contained in this Presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

Forward-looking statements and future performance

This Presentation contains forward-looking statements and comments about future events, including about the plans, strategies and objectives of Cryosite’s management and Cryosite’s expectations about the performance of its business. Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “opinion”, “predict”, “project”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on any forward-looking statement. While due care and attention has been used in the preparation of forward-looking statements, forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends which are based on interpretations of current market conditions, circumstances and events specific to the industry and markets in which Cryosite and its related bodies corporate and associated undertakings operate. Forward-looking statements including projections, expectations, guidance on future earnings and estimates concerning the timing and success of strategies, plans or intentions are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, contingencies and uncertainties and other factors, many of which are outside the control of Cryosite and cannot be predicted by Cryosite. Forward-looking statements may involve significant elements of subjective judgement and assumptions as to future events, which may or may not be correct, and therefore you are cautioned not to place undue reliance on such information. A number of important factors could cause Cryosite’s actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. Neither Cryosite nor any other person gives any representation, warranty, assurance or guarantee that the occurrence of the events expressed implied in any forward-looking statement will actually occur. The forward-looking statements are based on information available to Cryosite as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), Cryosite disclaims any obligation and makes no undertaking to provide any additional or updated information whether as a result of new information, future events or results or otherwise, or to reflect any change in expectations or assumptions.

Disclaimer

To the maximum extent permitted by law, Cryosite and its related bodies corporate and affiliates, and its officers, directors, partners, employees, agents and advisers: (i) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss, expense, damage or cost arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (ii) disclaim any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumption; and (iii) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Cryosite, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement. The information in this Presentation remains subject to change without notice.

2

The Cryosite Opportunity

==> picture [187 x 64] intentionally omitted <==

A market leading clinical trial and biological depot, positioned to capitalise on the exponential global growth in Ultra-Frozen and Cryogenic storage and logistics. Over the past three years, Cryosite has invested in the human capital, equipment, operational procedures, and regulatory systems to leverage this opportunity. Cryosite is poised to tap into a market that is expected to be the future of modern medicine, with the addressable market estimated to grow 5x in the next decade[1] .

3

1 Vi si ongain. (2023) 'Cel l & Gene Therapy Col d Chai n Logi sti cs Market Report 2023-2033', Vi si ongain. Avai l abl e at: https://www.vi si ongain.com/report/cell-gene-therapy-cold-chain-logistics-market-2023/

Agenda

==> picture [187 x 64] intentionally omitted <==

1. FY25 – Overview

2. FY25 – Financial Performance

3. Ultra-Frozen and Cryogenic

4. i. A Growth Engine

5. ii. Global Tailwinds

6. iii. Performance

7. FY26 – Strategic Priorities

4

FY25 – Another record year for Cryosite

• √ Record financial performance with double digit growth across revenue, gross

• profit, and EBITDA

• √ Our strongest operational volumes and quality results

• √ Commenced reporting on our Ultra-Frozen and Cryogenic revenue segment

• √ All on major client contracts extended multi-year agreements

• √ Capacity expansion through mezzanine extension ( 17% uplift in site capacity)

• √ External accreditation from: Australian Border Force (Australian Trusted Trader

Status), and EcoVadis (Gold Medal ESG rating)

• √ New revenue streams : large-capacity Cryogenic dry-shipper (photo in slide)

==> picture [187 x 64] intentionally omitted <==

==> picture [252 x 276] intentionally omitted <==

5

FY 25 - Financial Performance

A record financial performance leveraging Cryosite’s strategic position in Ultra-Frozen and Cryogenic storage and logistics:

Revenue $14.1m – an increase of 12% vs FY24 ($12.6m)

==> picture [12 x 12] intentionally omitted <==

• A cumulative increase of 18% vs FY23

EBITDA $3.4m – an increase of 19% vs FY24 ($2.8m)

==> picture [12 x 13] intentionally omitted <==

• A cumulative increase of 52% from FY23

NPAT $1.9m – an increase of 2% vs FY24 ($1.8m)

==> picture [12 x 12] intentionally omitted <==

• Income tax expenses increased $0.4m (160%) in FY25 due to our strong financial performance and the full utilisation of historical tax credits in FY24

• A cumulative increase of 34% vs FY23

==> picture [187 x 64] intentionally omitted <==

Cryosite Revenue and EBITDA (AUDm FY23 to FY25)

==> picture [422 x 320] intentionally omitted <==

----- Start of picture text -----

16.0
+12% 14.1
14.0
12.6
11.9
12.0
10.0
8.0
6.0
+19%
4.0 3.4
2.8
2.2
2.0
-
FY23 FY24 FY25 FY23 FY24 FY25
Revenue EBITDA
----- End of picture text -----

6

Ultra-Frozen and Cryogenic – A Growth Engine

==> picture [187 x 64] intentionally omitted <==

==> picture [320 x 189] intentionally omitted <==

----- Start of picture text -----

2
----- End of picture text -----

In FY25, Cryosite commenced reporting on our new Ultra-Frozen and Cryogenic revenue segment encompassing advanced therapies stored in temperatures ranging from -70°C to -196°C. These include:

==> picture [12 x 12] intentionally omitted <==

Cell and Gene Therapies (CGT)

==> picture [12 x 12] intentionally omitted <==

mRNA-based medicines (inc. vaccines)

==> picture [12 x 12] intentionally omitted <==

Biological samples

==> picture [12 x 12] intentionally omitted <==

Research and Development (R&D) materials

==> picture [12 x 12] intentionally omitted <==

==> picture [330 x 205] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

The global Cell and Gene Therapies market is projected to grow ~20%

==> picture [12 x 12] intentionally omitted <==

p.a.[1] over the next 10 years driven by:

Advancements in biotechnology

==> picture [12 x 13] intentionally omitted <==

Rising prevalence of chronic disease

==> picture [12 x 12] intentionally omitted <==

Increased R&D investment

==> picture [12 x 12] intentionally omitted <==

Regulatory support

==> picture [12 x 12] intentionally omitted <==

With a wealthy and ageing global population, GDP spending on Healthcare continues to rise

1,3 Vi si ongain. (2023) 'Cel l & Gene Therapy Col d Chai n Logi stics Market Report 2023-2033', Vi si ongain. Avai l abl e at: https://www.vi si ongain.com/report/cell-gene-therapy-cold-chain-logistics-market-2023/ 2 https://market.us/report/cell-and-gene-therapy-market/

7

Ultra-Frozen and Cryogenic - Global Tailwinds

==> picture [187 x 64] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

==> picture [13 x 14] intentionally omitted <==

==> picture [13 x 14] intentionally omitted <==

Cell and Gene Therapies are a major driver of our Ultra-Frozen and Cryogenic revenue segment This market is expected to grow significantly through the next decade as trial complexity increases and demand for compliant infrastructure intensifies : Cryosite is well positioned to capitalise on this growth First mover advantage: Limited competition in TGA regulated storage and distribution Track record: 20+ years experience handling Ultra-Frozen and Cryogenic materials via Cord Blood business TGA-licensed: for storage, labelling, and secondary packaging manufacturing steps, which can take several years and significant capital expenditure to obtain Equipment and technology: including one of Australia’s largest independent Cryogenic storage facilities and a large-scale Ultra-Frozen freezer farm

==> picture [12 x 12] intentionally omitted <==

Established client relationships : existing experience and trust from key global players

The growth potential for this segment is already materialising in Cryosite’s business

8

Ultra-Frozen and Cryogenic – Performance

==> picture [187 x 64] intentionally omitted <==

==> picture [12 x 12] intentionally omitted <==

==> picture [12 x 13] intentionally omitted <==

==> picture [12 x 12] intentionally omitted <==

==> picture [12 x 12] intentionally omitted <==

==> picture [12 x 12] intentionally omitted <==

==> picture [12 x 12] intentionally omitted <==

==> picture [12 x 12] intentionally omitted <==

Revenue $1.9m – an increase of 58% vs FY24 ($1.2m)

• a cumulative increase of 150% from FY23 ($0.7m)

EBITDA $0.8m – an increase of 65% vs FY24 ($0.5m)

• A cumulative increase of 169% from FY23 ($0.3m)

Clients/Sponsors – active clients/sponsors (up 27% vs FY24)

17% site footprint increase – through a mezzanine expansion

40% capacity uplift in Ultra-Frozen freezers

– Launch of large-capacity Cryogenic dry-shipper logistics enabling relocation of large-volumes of cryopreserved products in a single shipper

Systems – enhanced digitisation

Ultra-Frozen and Cryogenic Revenue and EBITDA (AUDm FY23 to FY25)

==> picture [416 x 315] intentionally omitted <==

----- Start of picture text -----

2.0
1.9
1.8
1.6
+58%
1.4
1.2
1.2
1.0
0.8
0.8 0.7
+65%
0.6
0.5
0.4
0.3
0.2
-
FY23 FY24 FY25 FY23 FY24 FY25
Revenue EBITDA
----- End of picture text -----

9

FY26 – Strategic Priorities

==> picture [187 x 64] intentionally omitted <==

==> picture [13 x 14] intentionally omitted <==

==> picture [13 x 14] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

==> picture [13 x 14] intentionally omitted <==

Securing a second premises

• to meet growing client demand. Cryosite’s strong balance sheet, pre-approved funding, and robust cashflow provide the means to acquire additional site capacity without requiring a capital raise

Strengthening our Ultra-Frozen and Cryogenic leadership

• expanding value for regulated storage and logistics customers

Continuing domestic and international partnership discussions

• to expand market access and capabilities

Leveraging operational data and digitisation

==> picture [249 x 274] intentionally omitted <==

• to deliver smarter reporting and improved decision-making value for our clients

How Cryosite will capitalise on this opportunity

10